The purpose of this study is to evaluate the safety and effectiveness of an investigational drug called MK-2206 in women with endometrial cancer that has returned or progressed despite prior treatment. Patients will be divided into two groups: those whose tumors contain a mutation in a gene called PIK3CA, and those without this mutation. This gene is involved in the AKT pathway.
MK-2206 works by turning off a protein called AKT. When AKT is turned on, signals are sent inside a cell that can cause abnormal cells to grow and divide faster; MK-2206 attempts to block these signals by turning off AKT. MK-2206 is a capsule that is taken orally (by mouth).